FindMyRecallSubscribe
Class I: serious health riskOngoing

Pfizer 4.2% Sodium Bicarbonate Injection Recall

4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of…

Pfizer Inc. · New York, NY

Risk level
Class I
Reported by FDA
Jan 24, 2024
Recall ID
D-0233-2024
Check your lot numberHow we source this data

Summary

Pfizer recalled 4.2% Sodium Bicarbonate Injection starting Dec 21, 2023. The FDA classified it as Class I (serious health risk) and published enforcement report D-0233-2024 on Jan 24, 2024. Reason: Presence of Particulate Matter; identified as glass. Status: Ongoing.

Why it was recalled

Presence of Particulate Matter; identified as glass

Product description

4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake Forst, IL 60045, NDC 0409-5534-24 (carton), 0409-5534-14 (case).

Lot numbers, UPCs & expiration codes

Lot GX1542, Exp. 01/01/2025

Where it was sold

Nationwide in the USA and Puerto Rico.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0233-2024
Classification
Class I
Status
Ongoing
Recall initiated
Dec 21, 2023
FDA report date
Jan 24, 2024
Quantity
34000 Cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Pfizer Inc.

Original FDA data

Every field from FDA enforcement report D-0233-2024, exactly as published.

Show all FDA fields
City
New York
State
NY
Status
Ongoing
Country
United States
Event ID
93681
Address
235 East 42nd Street
Code information
Lot GX1542, Exp. 01/01/2025
Postal code
10017-5703
Report date
Jan 24, 2024
Product type
Drugs
Recall number
D-0233-2024
Classification
Class I
Recalling firm
Pfizer Inc.
Product quantity
34000 Cartons
Reason for recall
Presence of Particulate Matter; identified as glass
Voluntary / mandated
Voluntary: Firm initiated
Product description
4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT Unit of Use Syringe, For Intravenous Use, Rx Only, 10 mL Syringe per Carton, Hospira, Inc., Lake Forst, IL 60045, NDC 0409-5534-24 (carton), 0409-5534-14 (case).
Distribution pattern
Nationwide in the USA and Puerto Rico.
Recall initiation date
Dec 21, 2023
Initial firm notification
Letter
Center classification date
Jan 17, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0233-2024, published Jan 24, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls